CompletedNCT00839852
A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
Researchers studied Cariprazine to find out how it affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–61Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Cariprazine to find out how it affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 61 years. Other eligibility criteria applied.
- Listed locations
- Costa Mesa and 64 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 31, 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 97
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, India, Malaysia, ...
- Age range
- From 18 Years to 61 Years
- Official registry ID
- NCT00839852
- Official title
Show the full official title
A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia
Recruitment & locations
CompletedCosta Mesa, United States · Long Beach, United States · Oceanside, United States
49 more locations
- Paramount, United States
- Riverside, United States
- Washington D.C., United States
- Bradenton, United States
- Kissimmee, United States
- Lake Charles, United States
- Baltimore, United States
- Flowood, United States
- Creve Coeur, United States
- Cincinnati, United States
- Charleston, United States
- Memphis, United States
- Houston, United States
- Irving, United States
- Vijaywada, India
- Visakhapatnam, India
- Ahmedabad, India
- Bangalore, India
- Mangalore, India
- Manipal, India
- Mysore, India
- Pune, India
- Jaipur, India
- Chennai, India
- Tirupati, India
- Kanpur, India
- Johor Bahru, Malaysia
- Kuala Lumpur, Malaysia
- Perak, Malaysia
- Arkhangelsk, Russia
- Gatchina, Russia
- Ivanovo, Russia
- Kazan', Russia
- Krasnodar, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Kherson, Ukraine
- Chernihiv, Ukraine
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Kyiv, Ukraine
- Odesa, Ukraine
- Ternopil, Ukraine
- Russia
Questions about this study
What did researchers investigate?
Researchers studied Cariprazine to find out how it affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 61 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia